Real-World Effectiveness and Safety of Sofosbuvir-Based Therapy in Chinese Children and Adolescents With Chronic HCV Infection: A Retrospective Multicentre Study.
9 affiliations
- 1The Third People's Hospital of Kunming City, Kunming, China.
- 2The People's Hospital of Fuyuan County, Qujing, China.
- 3The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
- 4The Fourth People's Hospital of Qinghai Province, Xining, China.
- 5The Fifth People's Hospital of Wuxi City, Wuxi, China.
- 6The First People's Hospital of Xuanwei City, Qujing, China.
- 7Gilead Sciences, Shanghai, China.
- 8Gilead Sciences, Foster City, California, USA.
- 9Gilead Sciences, Uxbridge, UK.
Abstract
Few direct-acting antiviral regimens are approved in China for children and adolescents with chronic hepatitis C virus (HCV) infection and data are limited on their efficacy and safety in this population. This retrospective, multi-centre study aimed to assess the real-world effectiveness and safety of ledipasvir/sofosbuvir (LDV/SOF) and sofosbuvir/velpatasvir (SOF/VEL) in Chinese paediatric patients. The study included patients aged 3-17 years from five hospitals across China who received either LDV/SOF or SOF/VEL for chronic HCV infection. The outcomes included the proportion of patients who achieved sustained virologic response at 12 weeks post-treatment (SVR12), normalisation rates of ALT and AST levels, and incidence of adverse events (AEs). A total of 129 patients from five sites were included and 128 completed 12 weeks of post-treatment follow-up. Mean age was 9.9 years (standard deviation, 3.9), with 30 (23.3%), 55 (42.6%), and 44 (34.1%) patients aged 3-6, 7-11, and 12-17 years, respectively, 84 (65.1%) were male, 62 (48.1%) were infected with genotype 3, and baseline ALT and AST levels were elevated in 64 (49.6%) and 75 (58.1%) patients, respectively. The SVR12 rate was 98.4% (126/128) in the overall population, remaining consistent across subgroups by sex, age, HCV genotype, or regimen. ALT and AST levels were normalised in all patients with available data. AEs were reported by 16.4% (21/128) of patients and none were serious. Collectively, this study demonstrated that LDV/SOF and SOF/VEL were highly effective and well tolerated in Chinese paediatric patients with chronic HCV infection.
Related
- Effectiveness of Contemporary Invisalign® Clear Aligners for Derotation and Deep Bite Correction of Different Degrees of Severity in Adolescents and Adults: A Retrospective Clinical Study
- Molecular mechanisms underlying the effectiveness of triiodothyroacetic acid (Triac) in patients with resistance to thyroid hormone β (RTHβ): a multicentre, international, retrospective cohort study.
- Disease burden of rotavirus infection and its complications among children under 14 years old with acute gastroenteritis in China: a multicentre and retrospective study
- A cluster analysis of neonates using clinical signs of possible serious bacterial infection at hospital admission in Kenya: A retrospective multicentre cohort study
- Effectiveness and safety of electroacupuncture as an adjunct to guideline-based usual care for acute lumbar disc herniation: a multicentre, randomised, sham-controlled trial protocol.
BibTeX
@article{liu2026realworld,
title = {{Real-World Effectiveness and Safety of Sofosbuvir-Based Therapy in Chinese Children and Adolescents With Chronic HCV Infection: A Retrospective Multicentre Study.}},
author = {Li Liu and Mei Li and Shishu Zhu and Yi Dong and Hongmei Zu and Ping Yu and Ruiling Liu and Yan Chen and Joshua Lin and Carl Gustafson and Heribert Ramroth and Lin Liu and Yanwen Luo},
journal = {Journal of viral hepatitis},
year = {2026},
month = oct,
doi = {10.1111/jvh.70253},
url = {https://europepmc.org/article/MED/42952280},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Real-World Effectiveness and Safety of Sofosbuvir-Based Therapy in Chinese Children and Adolescents With Chronic HCV Infection: A Retrospective Multicentre Study.
AU - Li Liu
AU - Mei Li
AU - Shishu Zhu
AU - Yi Dong
AU - Hongmei Zu
AU - Ping Yu
AU - Ruiling Liu
AU - Yan Chen
AU - Joshua Lin
AU - Carl Gustafson
AU - Heribert Ramroth
AU - Lin Liu
AU - Yanwen Luo
PY - 2026
DA - 2026/10/28
JO - Journal of viral hepatitis
DO - 10.1111/jvh.70253
UR - https://europepmc.org/article/MED/42952280
AB - Few direct-acting antiviral regimens are approved in China for children and adolescents with chronic hepatitis C virus (HCV) infection and data are limited on their efficacy and safety in this population. This retrospective, multi-centre study aimed to assess the real-world effectiveness and safety of ledipasvir/sofosbuvir (LDV/SOF) and sofosbuvir/velpatasvir (SOF/VEL) in Chinese paediatric patients. The study included patients aged 3-17 years from five hospitals across China who received either LDV/SOF or SOF/VEL for chronic HCV infection. The outcomes included the proportion of patients who achieved sustained virologic response at 12 weeks post-treatment (SVR12), normalisation rates of ALT and AST levels, and incidence of adverse events (AEs). A total of 129 patients from five sites were included and 128 completed 12 weeks of post-treatment follow-up. Mean age was 9.9 years (standard deviation, 3.9), with 30 (23.3%), 55 (42.6%), and 44 (34.1%) patients aged 3-6, 7-11, and 12-17 years, respectively, 84 (65.1%) were male, 62 (48.1%) were infected with genotype 3, and baseline ALT and AST levels were elevated in 64 (49.6%) and 75 (58.1%) patients, respectively. The SVR12 rate was 98.4% (126/128) in the overall population, remaining consistent across subgroups by sex, age, HCV genotype, or regimen. ALT and AST levels were normalised in all patients with available data. AEs were reported by 16.4% (21/128) of patients and none were serious. Collectively, this study demonstrated that LDV/SOF and SOF/VEL were highly effective and well tolerated in Chinese paediatric patients with chronic HCV infection.
SN - 1352-0504
SN - 1365-2893
ER -